AbbVie's Once-Daily Parkinson's Pill Juvmo Wins FDA Approval, with Nausea, Dizziness, and Headache Common in Trials Medical Daily 5d
AbbVie’s Juvmo Approval Adds More Fuel For Neuroscience Portfolio Growth Scrip Pharma Intelligence 6d
AbbVie just won FDA approval for a once-daily Parkinson's pill. Here's why it matters more than you think. The Motley Fool 1d Juvmo Biotech Pharma All sources
Iambic files IPO after signing up AbbVie as new partner pharmaphorum 11:58 Tue, 22 Sep Iambic Biotech Pharma
Market first claimed for York Cocoa Works innovative alt choc launch Confectionery Production 3d Textiles Biotechnology Pharma
Lancet publishes full petrelintide trial: About 10% weight loss, Nausea in 20% as amylin drug enters Phase 3 Medical Daily 3d Pharma The Lancet
Biogen’s litifilimab demonstrates rapid and durable efficacy in new 52-week Phase 2 data from ongoing Phase 2/3 amethyst study, reinforcing its potential as a first-in-class therapy for cutaneous Lupus Erythematosus Biogen (Press Release) 2d Biogen
Biotech company Tonix Pharmaceuticals announces plans for Hamilton manufacturing facility Ravalli Republic 2d Biotech Biotechnology
ISO 9001, 14001 and 45001 revisions: What changes and when to start Pharmaceutical Processing World 2d
FDA to consider fenebrutinib, BTK inhibitor for relapsing and primary progressive MS Rare Disease Advisor 2d Roche Science
